9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
The DOI matches its Crossref record; 90 of the 94 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc21-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc21-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the latest American Diabetes Association (ADA) [62], Italian Society of Diabetology (SID) [63] and KDIGO guidelines [64] differentiate the pharmacological approach to T2DM not just based on the target glycaemic values but also taking into account the indicators of high-risk or established atherosclerotic cardiovascular disease, CKD and heart failure.”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [62]
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644 · cited 1×
“temshasbeensupported in the literature in adolescents and adults with type 1 diabetes (16,17), and recent evidence suggests that a closed-loop system is superior to sensor-augmented pump therapy for glycemic control and reduction of hypoglycemia over 3 months of comparison in children and adults with type 1 diabetes (…”
BackgroundHermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Research works printed but not linked: 3
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
- Chiang, 2014, Type 1 diabetes through the life span: a position statement of the American Diabetes Association
- Lipska, 2018, Association of initiation of basal insulin analogs vs neutral protamine hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes, 53
Cited by
Items 701–800 of 975
Arab, J. P., Castro, L., GOMEZ, P. C., Vignolo, P., Arrese, M. A., Francisco Barrera, M., Castro, F., Díaz, L. A., Donoso, A., Elgueta, K., et al. (2021) · Revista médica de Chile · doi:10.4067/s0034-98872021000901360 · Cited by 8
Hoog, M. M., Smith, J. L., Yu, M. B., Peleshok, J. C., Mody, R., & Grabner, M. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.04.005 · Cited by 2
Lum, K. Y., Oppong, R., & Kigozi, J. (2022) · Asia Pacific Journal of Public Health · doi:10.1177/10105395221122643 · Cited by 2
Kim, B. K., & Seo, K. W. (2022) · Journal of Metabolic and Bariatric Surgery · doi:10.17476/jmbs.2022.11.2.13 · Cited by 3
The Glucagon-Like Peptide-1 Analogues therapy in the non-diabetic patients
Sienicka, A., Kubasik, K., & Pisula, A. (2023) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.127 · Cited by 3
Insulin Treatment of Diabetes Mellitus-Tight vs. Conventional Control
Emanuele, N., & Reaven, P. D. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_34 · Cited by 2
Chonko, K., Russo‐Alvarez, G., Isaacs, D. M., Wang, L., & Soric, A. (2023) · INNOVATIONS in pharmacy · doi:10.24926/iip.v14i2.5456 · Cited by 5
Lee, H., Chung, J., Yu, K., Park, S., & Lee, S. (2023) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1310 · Cited by 3
The diabetic patient between sustainability and effectiveness of new treatments
Ferrara, F., Zovi, A., Langella, R., Nava, E., & Trama, U. (2023) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-023-01296-0 · Cited by 2
Serowik, T. C., & Pantalone, K. M. (2023) · Journal of Osteopathic Medicine · doi:10.1515/jom-2023-0179 · Cited by 5
“…outcomes, SGLT-2i and GLP-1RA therapies are now considered as options for treatment, independent of A 1c levels, and are instead indicated based on the presence of established ASCVD or notable risk factors for arteriosclerotic vascular disease (ASVD), as well as heart failure and/or CKD [45].”
BackgroundCinnamon Modulates Toll-Like Receptors: a New Therapeutic Approach for Diabetes
Niknejad, A., Razavi, S. M., Hosseini, Y., Arab, Z. N., Abdolghaffari, A. H., & Momtaz, S. (2023) · Revista Brasileira de Farmacognosia · doi:10.1007/s43450-023-00460-0 · Cited by 5
Lertwanichwattana, T., Suwannahitatorn, P., Mungthin, M., & Rangsin, R. (2024) · PLoS ONE · doi:10.1371/journal.pone.0298010 · Cited by 3
Nguyen, C., Crowe, C. L., Kuti, E. L., Donato, B. M. K., DJARAHER, R. L., SEMAN, L. J., Graeter, N., Power, T. P., Mehra, R., & Willey, V. J. (2014) · Journal of health economics and outcomes research · doi:10.36469/001c.92368 · Cited by 3
Nandave, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-7568-2_1 · Cited by 2
Bando, H. (2021) · Asploro Journal of Biomedical and Clinical Case Reports · doi:10.36502/2021/asjbccr.6245 · Cited by 2
Figueiredo, B. S., Ferreira, F. B. D., Barbosa, A. M., dos Santos, C., Ortsäter, H., & Rafacho, A. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120026 · Cited by 2
Vikulova, O. K., Galstyan, G. R., & Shestakova, M. (2022) · Diabetes Mellitus · doi:10.14341/dm12803 · Cited by 3
Fonseca, V. A., Sood, M., & Galindo, R. J. (2021) · Clinical Diabetes · doi:10.2337/cd20-0121 · Cited by 2
Clinical Response to Xultophy Possibly Varies from Each Different Metabolic Function
Bando, H., Kazuki, S., Tomoya, O., Naoki, K., Hatakeyama, S., Kobayashi, T., & Noboru, I. (2021) · Edelweiss Applied Science and Technology · doi:10.33805/2576-8484.190 · Cited by 2
Ruyatkina, L. A., Ruyatkin, D. S., & Iskhakova, I. S. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-7-33-44 · Cited by 2
Antihyperglycemic Algorithms for Type 2 Diabetes: Focus on Nonglycemic Outcomes
Solis‐Herrera, C., Cersósimo, E., & Triplitt, C. L. (2021) · Diabetes Spectrum · doi:10.2337/ds20-0067 · Cited by 3
Westman, K., Imberg, H., Wijkman, M. O., Hirsch, I. B., Tuomilehto, J. O., Dahlqvist, S., & Lind, M. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108110 · Cited by 2
Addressing Overbasalization to Achieve Glycemic Targets
Cowart, K., Franks, R. B., Pane, O., Murphy, E., & Oldziej, K. (2022) · ADCES in Practice · doi:10.1177/2633559x211068884 · Cited by 2
Aron‐Wisnewsky, J., Lefevre, C., & Bindels, L. B. (2022) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2022.01.004 · Cited by 4
Shi, F., Yue, J., Jiang, Y., Yang, M., Gu, Z., Ma, J., & Li, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.787704 · Cited by 2
“Following the newest American Diabetes Association ADA guideline, the early introduction of insulin should be considered if symptoms of hyperglycaemia are present or when HbA1c levels or blood glucose level are very high (Association, 2021).”
Yan, X., Feng, C., Lou, Y., & Zhou, Z. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01262-8 · Cited by 3
Pioglitazone: Reviewed and Renewed
Charbonneau, M. S., & Capoccia, K. L. (2022) · ADCES in Practice · doi:10.1177/2633559x221093294 · Cited by 2
Kim, Y., Huh, J. H., Lee, M., Kang, E. S., Soo, B., & Lee, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.880164 · Cited by 2
An Interesting Experience with Empagliflozin: Unidentified Body Odor
Uyaroğlu, O. A. (2021) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2021.554 · Cited by 2
Diabetes mellitus: what the neurologists need to know
Stephens, J. W., Williams, D. M., & Chudleigh, R. A. (2022) · Practical Neurology · doi:10.1136/pn-2022-003395 · Cited by 2
Liu, Z., Xiao, L., Jin, C., Xiao, J., & Zhao, W. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s373712 · Cited by 4
Petrosan, A., Santeusanio, A. D., Khaim, R., & Delaney, V. B. (2022) · Progress in Transplantation · doi:10.1177/15269248221122869 · Cited by 2
Optimizing the Current Type 2 Diabetes Antidiabetics with Nanotechnologies: Where Do We Stand?
Abderrahmani, A., Szunerits, S., Dalle, S., & Boukherroub, R. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839165498-00092 · Cited by 3
A rare case report of combined metformin-associated lactic acidosis and diabetic ketoacidosis
Kularathne, Y., Goh, S., & Pothiawala, S. E. (2022) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-022-00161-5 · Cited by 2
Qureshi, N., Desousa, J., Siddiqui, A. Z., Drees, B. M., Morrison, D. C., & Qureshi, A. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032732 · Cited by 2
Sustainability and evolution of health care regarding treatments concerning type 2 diabetes mellitus
Ferrara, F., Zovi, A., Langella, R., Cavallaro, F., Nava, E., Trama, U., & Vitiello, A. (2023) · Ethics Medicine and Public Health · doi:10.1016/j.jemep.2023.100890 · Cited by 2
Management of Heart Failure in Patients With Diabetes Mellitus in the UAE: A Call to Action
Sabbour, H. M., & Ahmad, A. (2023) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484231162248 · Cited by 2
“63”
BackgroundDiabetes in Old Age: Particularities and Specifics
Weber, P., Weberová, D., & Meluzínová, H. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1002479 · Cited by 3
Müller‐Wieland, D., Brandts, J., Verket, M., Marx, N., & Schütt, K. S. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_537 · Cited by 4
Shestakova, M. V., As, A., Antsiferov, M. B., Bardymova, T. P., Valeeva, F. V., Galstyan, G. R., Demidova, T. Y., Karpova, I. A., Киселева, Т. П., Mayorov, A. Y., et al. (2022) · Diabetes Mellitus · doi:10.14341/dm12848 · Cited by 2
Significance of Educational Literature and Diabetes Log Sheet on Hemoglobin A1c
Padda, J., Khalid, K., Zubair, U., Hennawi, H. A., Khedr, A., Patel, V., Cooper, A. C., & Jean-Charles, G. (2022) · Cureus · doi:10.7759/cureus.21667 · Cited by 2
de Vries, R., Reinders, E. F. H., de Carvalho, D. F., de Meulengraaf, E. M. W. L. C. V., Gorp, P. M. E. V., Poppel, P. W., Kaymak, U., Hilbers, P. A. J., van Riel, N. A. W., & Haak, H. R. (2024) · medRxiv · doi:10.1101/2024.12.13.24318201 · Cited by 2
A case report of euglycemic ketoacidosis due to dapagliflozin treatment
Calapkulu, M., Sencar, M., Ünsal, İ. Ö., Bostan, H., & Çakal, E. (2021) · Turkish Journal of Internal Medicine · doi:10.46310/tjim.877156
Houssarini, J. A., Brnabic, A. J. M., & Obaid, M. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01184-x · Cited by 1
The Role of Physicians’ Digital Tools in Pharmacological Management of Type 2 Diabetes Mellitus
Janež, A., Ješe, R., Haluzík, M., & Rizzo, M. (2022) · Medicina · doi:10.3390/medicina58081061 · Cited by 2
Prior to versus after Metformin Treatment—Effects on Steroid Enzymatic Activities
Gasser, B. A., Escher, G., Calin, A.-E., Deppeler, M., Marchon, M., Mistry, H. D., Kurz, J., & Mohaupt, M. G. (2023) · Life · doi:10.3390/life13051094 · Cited by 2
Qarni, A. A. A., AlSubaiee, M., Husain, M., Alkhazmari, G., AlQahtani, A., Aldossary, I., Gado, W., Albahrani, Z., AlMukhaylid, S., Alarfaj, A., et al. (2023) · Series of Endocrinology Diabetes and Metabolism · doi:10.54178/jsedmv5i2004 · Cited by 2
Fawzy, E. F., Elattar, M. M., Badry, M. A. E., & Khashab, K. M. A. (2024) · Egyptian Pediatric Association Gazette · doi:10.1186/s43054-024-00311-0 · Cited by 2
Bubeck, A., Naïditch, N., Hehn, C., Hamamouche, N., Pascal, C., & Thébaut, E. J.-F. (2025) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.12.005 · Cited by 1
Empagliflozin-based quadruple oral therapy for type 2 diabetes: a prospective cohort study
Moosaie, F., Abedinzadeh, S., Rabizadeh, S., Daneshvar, K., Noorafrooz, M., Mojtahedi, F., Deravi, N., Abhari, S. M. F., Ramezani, A., Meysamie, A., et al. (2025) · Scientific Reports · doi:10.1038/s41598-024-84993-x · Cited by 4
Tajik, A., Mahdavizadeh, V., Hadizadeh, F., & Shakour, N. (2025) · Current Diabetes Reviews · doi:10.2174/0115733998349193250207045239 · Cited by 1
Revascularization of coronary chronic total occlusion in patients with end stage renal disease
Tsai, C.-T., Lu, Y., Huang, W.-C., Huang, S., Teng, H.-I., Tsai, Y., Lee, W.-L., & Lu, T. (2025) · Scientific Reports · doi:10.1038/s41598-025-91447-5 · Cited by 1
“Explanations of high prevalence and better survival of ESRD in recent years are because of improve in dialysis care and treatment of co-morbidities such as diabetes mellitus, hypertension and coronary artery disease from both recent advancement in medications and devices 19–21 .”
Çakmak, R., Çaklılı, Ö. T., Kapar, C., Çatma, Y., Bayramlar, O. F., Çalıkoğlu, F., Karşıdağ, K., & Dınççağ, N. (2025) · Endocrine Regulations · doi:10.2478/enr-2025-0006 · Cited by 1
“The latest practice guidelines focus on individual patient characteristics, including age, present comorbidities, and risk of hypoglycemia when selecting a treatment (Inzucchi et al. 2015; American Diabetes Association 2021).”
Chou, L., Raji, M. A., Holmes, H. M., & Kuo, Y. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-087694 · Cited by 1
“27 With the mixed findings from the literature, we sought to clarify how the type of antidiabetic medication affects the risk of new episodes of depression by designing a longitudinal population-based study.”
Mayabhate, M. M., Kapure, N., & Sharma, A. (2025) · International Journal of Advances in Medicine · doi:10.18203/2349-3933.ijam20251937 · Cited by 2
Zhang, H., Chen, J., Zhao, Q., & Zhang, B. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1566101 · Cited by 1
“Metformin is the first line drug and the basic drug in drug combinations to control hyperglycemia in T2DM patients, which is recommended to be kept in the treatment regimen of diabetes without contraindications (9).”
Turhan, B., Sağlam, S., Yücel, M. O., Dalaslan, R. E., Sungur, M. A., Demir, F., Karaduman, Z. O., & Arıcan, M. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1691294 · Cited by 6
Mohebbi, A., Kjøller, N.-K., Johansen, A. R., Bengtsson, H. L., Jensen, M. L., Stallknecht, B. M., & Mørup, M. (2025) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc58623.2025.11253142 · Cited by 1
Keng, C., Thor, S. M., Balasubramaniam, R., & Pretorius, F. (2025) · Cureus · doi:10.7759/cureus.99664 · Cited by 1
Winberg, D., Panchang, S. V., Nauman, E., Mohundro, B. L., Tang, T., Price‐Haywood, E. G., Onufrak, S. J., Shi, L., & Bazzano, A. N. (2026) · Patient Preference and Adherence · doi:10.2147/ppa.s596366 · Cited by 2
“Third, participants frequently referenced broader aspects of insurance design, such as deductibles and medications not included in the ZDC benefit, which may limit the perceived impact of copay elimination.”
Badnjević-Čengić, A., Škrbić, R., Softić, A., Bego, T., Meseldžić, N., Stojaković, N., Crnčević, N., Deumić, S., Kadić, D., Mooranian, A., et al. (2026) · Technology and Health Care · doi:10.1177/09287329261438698 · Cited by 1
“Insulin resistance and 𝛽 -cell function were calculated using the HOMA2 Calculator.”
Pendhari, A. T., R., S. R. V., Bantwal, G., Kumar, K. M. P., Reddy, S., Kannan, S., & Reddy, M. M. (2026) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-026-01664-5 · Cited by 1
Alanazi, M., Al‐kuraishy, H. M., Mohamed, A. A., Abass, S. A., Shokr, M. M., Alruwaili, M., & Batiha, G. E. (2026) · Current Nutrition Reports · doi:10.1007/s13668-026-00773-1 · Cited by 1
Clister, D., Chandra, Q. M., Tan, M.-S., Gunawan, M. C., Bibi, A., Ahmed, A., Bastian, M., Meesakul, P., Cao, S., Kim, B., et al. (2026) · Journal of Nutrition · doi:10.1016/j.tjnut.2026.101596 · Cited by 1
A population-level approach to the treatment of psychiatric disorders
Blanco, C., & Olfson, M. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03738-6 · Cited by 1
“…and receptor characteristics of the tumor has shown to be superior to non-algorithmic based care [4], whereas the treatment of diabetes is guided by diabetes type (I versus II), glycemic control and non-glycemic outcomes such as atherio-sclerosis, kidney function and heart ejection fraction [5].”
Li, Z., Zhang, S., & Liu, B. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-120259 · Cited by 1
ROLE OF OCTREOTIDE IN MANAGEMENT OF SULPHONYLUREA - INDUCED REFRACTORY HYPOGLYCEMIA : A CASE REPORT
KOTHARI, A. R., & Shah, K. (2021) · INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH · doi:10.36106/ijsr/9600245 · Cited by 3
Shi, F., Li, H., Kong, L.-C., Shen, L., Jiang, Y., Gu, Z., & Ge, H. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.658059 · Cited by 1
Atal, S., Joshi, R. P., Misra, S., Fatima, Z., Sharma, S., Balakrishnan, S., & Singh, P. (2021) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2021-0189 · Cited by 1
New Perspectives in COPD Management
Yawn (2021) · The Journal of Family Practice · doi:10.12788/jfp.0220 · Cited by 2
Eruptive xanthomas secondary to severe hypertriglyceridemia
Hopper, W., Veria, S., Glosser, L. D., Garg, A., Awad, M. T., Smith, J. D., & Din, S. U. (2021) · Global Journal of Medical and Clinical Case Reports · doi:10.17352/2455-5282.000142 · Cited by 1
Sklyanik, I. A., & Shestakova, M. V. (2021) · Terapevticheskii arkhiv · doi:10.26442/00403660.2021.10.201070 · Cited by 1
Ruiz, T., Dutour, A., Denis, D., Comet, A., Eisinger, M., Houssays, M., Darmon, P., Boullu, S., Soghomonian, A., David, T., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10102421 · Cited by 2
Mannucci, E., & Ghetti, G. (2022) · Farmeconomia Health economics and therapeutic pathways · doi:10.7175/fe.v23i1.1539 · Cited by 1
Nagao, M., Harada, T., Tanimura‐Inagaki, K., Kobayashi, S., Fukuda, I., Sugihara, H., & Oikawa, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-28138-6 · Cited by 2
Mohammadtabar, M., Fazeli, A., Parsai, N., Aboulfathiyarmohammadyar, Z., Shafiei, E., Khaledi, M., Zaremoghadam, E., Sisakht, A. R., Mohammadi, S., & Mardanparvar, H. (2023) · Journal of Nephropathology · doi:10.34172/jnp.2023.21444 · Cited by 1
“SGLT2i application also reduced body weight, blood pressure, and mortality rate (7-10).”
BackgroundChou, L., Raji, M. A., Yu, X., & Kuo, Y. (2023) · International Journal of Behavioral Medicine · doi:10.1007/s12529-023-10172-3 · Cited by 3
El Hígado graso (parte 2): enfoque clínico y tratamiento
Ortíz, J. E. P., Luque, C. B. S., & Quiróz, R. J. O. (2023) · Revista Colombiana de Gastroenterología · doi:10.22516/25007440.979 · Cited by 1
Qiu, W., Cai, A., Xiao, X., Gao, Z., Feng, Y., & Li, L. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01046-5 · Cited by 1
Type 2 diabetes: treatment recommendations for reducing the risk of complications
Syed, H. (2023) · Nursing Standard · doi:10.7748/ns.2023.e11997 · Cited by 3
Place of metformin in modern clinical guidelines for the treatment of type 2 diabetes mellitus
Моргунова, Т. Б., Glinkina, I. V., Дмитриевна, П. Е., Zorina, A. A., & Fadeev, V. V. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-211 · Cited by 2
Physiotherapy in the treatment of the metabolic syndrome associated with the right-sided scoliosis
Riabenko, I., Galicheva, К., Beloshenko, K., Riabtsev, R., & Voroshylova, Y. (2023) · Physical rehabilitation and recreational health technologies · doi:10.15391/prrht.2023-8(3).02 · Cited by 5
Naidoo, P., Pauly, B., Variava, E., Pillay, S., Bayat, Z., Daya, R., Michelle, C., Naidoo, K., Lauren, S., & Bhana, S. (2023) · Wits Journal of Clinical Medicine · doi:10.18772/26180197.2023.v5n3a1 · Cited by 1
Preconception Care for Individuals with Diabetes
Mukherjee, S. M., Dawson, A., & Carey, K. M. (2023) · EMJ Diabetes · doi:10.33590/emjdiabet/10305435 · Cited by 1
Pharmacy and neighborhood-level variation in cash price of diabetes medications in the United States
Warraich, H. J., Siddiqi, H. K., Li, D. G., van Meijgaard, J., & Vaduganathan, M. (2023) · PLoS ONE · doi:10.1371/journal.pone.0294164 · Cited by 1
“We used all-payer US pharmacy data of chain and independent pharmacies across all 50 states [9].”
BackgroundMethodNAFLD, the hepatic manifestation of the metabolic syndrome
Chaudhury, T., Brodosi, L., Marchesini, G., Mitra, S. K., & Petroni, M. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00055-4 · Cited by 2
Ali, A. M., Cobran, E. K., & Young, H. N. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01388-5 · Cited by 1
“Participants who were unable to access prescription medi - cations (RR 2 Multivariable associations between factors of influence in diabetes management and health outcomes additional agents like insulin may be considered in certain cases such as high A1C levels [30].”
Habas, E. M., Habas, A. M., Elzouki, I., Alfitori, G. B., Arrayes, E., Rayani, A., Farfar, K., Habas, E., & Elzouki, A.-N. Y. (2024) · Journal of Diabetes and Endocrine Practice · doi:10.1055/s-0044-1782673 · Cited by 1
Almazrouei, R. A., Siddiqua, A. R., Alanqar, A., Govender, R. D., & Al-Shamsi, S. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111763 · Cited by 1
Zhang, W., Wang, C., Wang, H., Tang, J., Zhang, H., Zhu, J.-Y., Zheng, X., Luo, S.-H., & Ding, Y. M. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i7.1477 · Cited by 1
Diabetic kidney disease in rural Australia: prevention, management, treatment and way forward
Ross, A. G., Mondal, U. K., Anyasodor, A. E., Mahmood, S., Astawesegn, F. H., Huda, M. M., Thapa, S., Aychiluhm, S. B., Giri, S., Rahman, M. F., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1561566 · Cited by 1
“Sodium-glucose cotransporter-2(SGLT2) inhibitors and Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are regarded as excellent second-line agents for people with CKD (9, 22, 36, 37).”
Wu, A., Wu, Y., Song, M., Chen, W., Xu, K., Wu, M., & Lin, L. (2025) · Scientific Reports · doi:10.1038/s41598-025-13014-2 · Cited by 3
“…findings from cardiovascular outcome trials demonstrate that GLP-1RA significantly mitigates the risk of major adverse cardiovascular events in patients with type 2 diabetes, thus warranting its prioritized use in individuals with diabetes accompanied by ASCVD or ASCVD risk factors 11,12 .”
Bhattacharyya, A., Kochhar, R., & Kumari, M. (2025) · Journal of Conservative Dentistry and Endodontics · doi:10.4103/jcde.jcde_285_25 · Cited by 1
“While Tavakolinejad Kermani et al . used a 10% HbA1C threshold, [16] our study followed the American Diabetes Association 2026 guidelines, [17] using 7% as the cutoff for categorizing participants.”
Welcome to the Cardiovascular Outcomes Trials Issue
Coleman, C. I., & Costa, O. S. (2021) · Future Cardiology · doi:10.2217/fca-2021-0028 · Cited by 1
Decision Points in the Management of Patients with Diabetic Kidney Disease
Weir (2021) · The Journal of Family Practice · doi:10.12788/jfp.0217 · Cited by 1
Sakurai, Y., Bando, H., Ogawa, H., Nagahiro, S., Nakanishi, M., & Watanabe, O. (2021) · Journal of Diabetes Metabolic Disorders & Control · doi:10.15406/jdmdc.2021.08.00223 · Cited by 1
Utilizing CGM Ambulatory Glucose Profiles to Optimize Diabetes Management
Miller (2021) · The Journal of Family Practice · doi:10.12788/jfp.0226 · Cited by 2
Haluzı́k, M., Kubíčková, M., Veselý, J., Linhart, A., Prázný, M., Škrha, J., Táborský, M., & Málek, F. (2021) · Vnitřní lékařství · doi:10.36290/vnl.2021.108 · Cited by 1
How far are we from predicting multi‐drug interactions during treatment for COVID‐19 infection?
Lozano, B., Santibáñez, J., Severino, N., Saldías, C., Vera, M., Retamal, J., Torres, S., & Barrera, N. P. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15819 · Cited by 1
Weber, P., Meluzínová, H., & Weberová, D. (2022) · Klinická farmakologie a farmacie · doi:10.36290/far.2021.027 · Cited by 1
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-12-04
- Volume
- 44
- Issue
- Supplement_1
- Pages
- S111-S124
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4254445254
- Cited by
- 972
- References
- 94
- Citations by year
- 2026: 29 · 2025: 55 · 2024: 86 · 2023: 148 · 2022: 334 · 2021: 318 · 2020: 1
- FWCI
- 30.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- pharmacotherapy, diabetes management, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Endocrinology, Humans, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.